ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CAPR vs ALT // FORWARD P/E MULTIPLE

Capricor Therapeutics Inc. (NASDAQ) VS. Altimmune Inc. (NASDAQ) • 15-METRIC TALLY: CAPR 2 — ALT 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAPR VS. ALT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CAPR ALT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -34.70% -0.30 ALT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -18.86% -16.23% -2.63 ALT /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 105.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.38 1.30 +2.08 CAPR /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 ALT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.6 26.7 +14.93 CAPR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $385.5M $416.3M -$30.8M ALT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CAPR REV ALT REV CAPR GROSS % ALT GROSS % CAPR FCF ALT FCF
FY 2025 $0 $41.0K — — -$72.7M -$67.5M
FY 2024 $22.3M $20.0K — — -$41.2M -$79.8M
FY 2023 $25.2M $426.0K — — -$25.6M -$75.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAPR // BETA —
ALT // BETA —